10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

18 November 2020 - BEAM Alliance

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign.

22 January 2021 - BEAM Alliance

BEAM Alliance Joined The One Health Good Practices For The Successful Management Of Antimicrobial Resistance

The BEAM Alliance decided to join the Call To Action of the AMR Stakeholder Network, supported by the European Public…

BEAM News
Member News
Events

Latest news of BEAM Alliance

22 January 2021 - BEAM Alliance

BEAM Alliance Joined The One Health Good Practices For The Successful Management Of Antimicrobial Resistance

The BEAM Alliance decided to join the Call To Action of the AMR Stakeholder Network, supported by the European Public…

18 November 2020 - BEAM Alliance

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign.

09 November 2020 - BEAM Alliance

Antibiorésistance : Anticiper une nouvelle crise sanitaire

Florence Séjourné, présidente de BEAM Alliance : « Il faut anticiper les investissements en R&D dès maintenant pour avoir un…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

29 April 2021 - DEINOVE

DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Priority Research Program

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial…

14 April 2021 - BioVersys AG

BioVersys receives €20 million in EU financing to support development of new antibiotics

“Being the first Swiss biotech company to receive a venture loan from the EIB is an independent validation of the…

06 April 2021 - Da Volterra

Da Volterra Receives FDA Fast Track Designation for its Novel Microbiome Protector DAV132

The company’s lead product-candidate, DAV132, is the world most advanced product protecting against the clinical consequences of microbiome dysbiosis. It…

31 March 2021 - Aptorum Group Ltd

Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based…

29 March 2021 - Destiny Pharma plc

Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal…

17 March 2021 - MaaT Pharma

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. The product is characterized by a high…

page 1/28

Events

27 May 2021

Free Webinar: Revisiting and Rebuilding Clinical Development for Antimicrobial Resistant Drugs – Lessons Learned During the COVID Pandemic

In this webinar, we bring together AMR experts to discuss how we can use the momentum from the pandemic to…

12 May 2021

ChinaBio® Partnering Forum 2021 – Shanghai and Digital

ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China. This year’s hybrid event enables…

10 May 2021

Virtual AMR Innovation Mission UK 2021

All topics covered contribute to the global fight against AMR! Three inspiring afternoons with keynotelectures, funding opportunities, international matchmaking and…

29 April 2021

REVIVE Webinar: AMR R&D efforts in the CMC and formulation arena: Do it right the first time!

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

20 April 2021

Anti-Infectives Drug Development – Digital Event

Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been…

22 March 2021

BIO-Europe Spring® Digital — 15th International Partnering Conference

The fifteenth annual BIO-Europe Spring® conference is the premier springtime partnering conference for the life science industry. For its 2021…

04 March 2021

GARDP: Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance

This webinar will focus on how we can apply the lessons learned from COVID-19 to tackle drug resistance and ensure…

25 February 2021

REVIVE Webinar: From discovery to the pre-clinical antimicrobial candidate

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

14 January 2021

REVIVE Webinar: Manipulating the host response to treat infections

Presentations: 1.) Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock): - Host…

page 1/9